试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
编号:NCT05493501登记状态:提前终止企业 / 申办者:EQRx International, Inc.
药物 / 成分:Aumolertinib monotherapy、Osimertinib monotherapy、Pemetrexed、Cisplatin
登记的停止原因(原文):The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with aumolertinib.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-02
Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy
编号:NCT05678881登记状态:提前终止企业 / 申办者:Receptor Life Sciences
药物 / 成分:High dose RLS103、placebo inhaled powder、Low dose RLS103
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-01
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
编号:NCT02718300登记状态:提前终止企业 / 申办者:Incyte Corporation
药物 / 成分:Parsaclisib、Parsaclisib、Ruxolitinib、Parsaclisib
登记的停止原因(原文):A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-01
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
编号:NCT03958630登记状态:提前终止企业 / 申办者:National Institute of Mental Health (NIMH)
药物 / 成分:11C-ER176、11C-PIB、Positron Emission Tomography (PET) Scan
登记的停止原因(原文):PI closed the protocol due to low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-01
A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
编号:NCT04947579登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:CC-99677、Placebo
登记的停止原因(原文):The study has been terminated due to Non-Safety reasons because of lack of efficacy in the short-term acute phase.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-01
Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
编号:NCT05309512登记状态:提前终止企业 / 申办者:Jiangsu Alphamab Biopharmaceuticals Co., Ltd
药物 / 成分:KN052
登记的停止原因(原文):Based on the differentiated R\&D strategy, the sponsor applies for the termination of the project.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-01
Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound
编号:NCT05317442登记状态:提前终止企业 / 申办者:Taipei Medical University WanFang Hospital
药物 / 成分:Fespixon Cream
登记的停止原因(原文):Study halted prematurely and will not resume.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-30
A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
编号:NCT04281420登记状态:提前终止企业 / 申办者:Antengene Therapeutics Limited
药物 / 成分:ATG-019、ATG-019 + Niacin ER
登记的停止原因(原文):Because the sponsor modified the study-product development strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-30
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
编号:NCT04407442登记状态:提前终止企业 / 申办者:University of California, San Francisco
药物 / 成分:Azacitidine、Daratumumab、Dexamethasone
登记的停止原因(原文):Slow enrollment and change in sponsor direction
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-30
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
编号:NCT04476797登记状态:提前终止企业 / 申办者:Galera Therapeutics, Inc.
药物 / 成分:GC4711 +SBRT、Placebo +SBRT
登记的停止原因(原文):Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis
查看官方原始记录 ↗